Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

337.90 +2.03 (+0.60%)
Streaming Delayed Price Updated: 10:29 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 438,341
Open 336.07
Bid (Size) 337.82 (2)
Ask (Size) 338.00 (5)
Prev. Close 335.87
Today's Range 336.07 - 338.88
52wk Range 276.83 - 384.44
Shares Outstanding N/A
Dividend Yield 1.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks That Could Benefit From the Ozempic Craze
Is it time to load up on these weight-loss stocks? 
Via The Motley Fool
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome... 
Via Benzinga

Performance

YTD
-7.42%
-7.42%
1 Month
+6.72%
+6.72%
3 Month
-7.48%
-7.48%
6 Month
+1.05%
+1.05%
1 Year
+17.17%
+17.17%

More News

Read More
Novo Nordisk's Obesity Drug May Find Place On World Health Organization's 'Essential Medicines List'
Via Benzinga
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
Via Investor's Business Daily
Why Shares of ProQR Therapeutics Dropped on Wednesday
Via The Motley Fool
Check Out What Whales Are Doing With LLY
Via Benzinga
Will Chart Analysts Notice Bad Omen on Eli Lilly's Chart
Via Benzinga
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?
Via The Motley Fool
1 Stock Down 9% in 2023 to Buy and Hold Forever
Via The Motley Fool
3 Dividend Stocks That Have Been Paying Investors Since the 1800s
Via The Motley Fool
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Via The Motley Fool
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Via The Motley Fool
Mid-Cap Monday: ETF Fund Flows
Via Benzinga
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Via MarketBeat
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
Via The Motley Fool
Don't Be Fooled by These 3 Value Traps
Via MarketBeat
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
Via Investor's Business Daily
Why Novartis Shares Are Trading Higher Premarket Today
Via Benzinga
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Via Investor's Business Daily
7 Hot Stocks To Turn $1,000 Into $10,000 By 2030
Via InvestorPlace
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Via Benzinga
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.